Trials / Completed
CompletedNCT02609737
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study has 3 steps and not everyone will have all 3 steps done. The overall goals are to see if a new experimental drug is safe to image (step 1) and treat neuroendocrine tumors (step 2 and 3).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | PET/CT Imaging | |
| RADIATION | 68Ga-DOTA-JR11 | |
| RADIATION | 177Lu-DOTA-JR11 |
Timeline
- Start date
- 2015-11-13
- Primary completion
- 2020-12-10
- Completion
- 2020-12-10
- First posted
- 2015-11-20
- Last updated
- 2022-02-01
- Results posted
- 2022-02-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02609737. Inclusion in this directory is not an endorsement.